Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Trumenba in Healthy Young Adults
NCT01352845Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2013
- Primary completion
- Feb 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 3 trial of meningococcal group B vaccine in meningococcal group B disease, sponsored by Pfizer. Started May 2013; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal group B disease
Beyond the preview
Go deeper on NCT01352845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352845.